Muscular dystrophy refers to a group of over 30 progressive muscle weakening disorders that are often disabling. Most forms of muscular dystrophy have symptoms that begin in early childhood, but some have symptoms that do not appear until early to late adulthood. The most common form of muscular dystrophy is Duchenne muscular dystrophy, which affects approximately 1 in 3,500 males. Girls are less affected by the common types of muscular dystrophy, which are inherited in an X-linked manner. There is no cure for any type of muscular dystrophy, and treatment is supportive and often includes use of wheelchairs, walkers, and breathing aids. Many forms of muscular dystrophy have an average life expectancy of late teens to early twenties, but with the introduction of supportive care and more information available about the disorders, the life expectancy is increasing.
Muscular Dystrophy Bioinformatics Tool
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Muscular Dystrophy below!
For more information on how to use Laverne, please read the How to Guide.
We have 526 products for the study of Muscular Dystrophy that can be applied to Western Blot, Chromatin Immunoprecipitation, Flow Cytometry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry from our catalog of antibodies and ELISA kits.
Muscular Dystrophy is also known as Dystrophies, Muscular, Hereditary Progressive Muscular Dystrophy, Muscular Dystrophies, Myodystrophies, Myodystrophy.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.